Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
The end of three licensed assets sees Takeda take a step back from autologous cell therapy.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
Rusfertide’s big readout will now not come until 2025.
A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.
The group’s B7-H4-targeting bispecific is out, in favour of Seagen’s ADC.
First-in-human trial initiations feature anti-PSMA radioligands, KRAS G12D, Nectin-4 and more.